All News
ACR Best Abstracts - Day 2
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for #ACRbest abstracts today:
Can Neural Networks Answer Important Diagnostic Dilemmas in Rheumatology?
An interesting study presented at ACR22 looked at whether neural networks can distinguish seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) using hand MRI data based on the structural inflammation patterns.
Read Article
ATOM study, Abs 1314, greater proportion of men with OP on abaloparatide vs placebo met the definition of a >3% responder at the LS, TH, and FN. #ACR22 @RheumNow https://t.co/q6gcX5Azts https://t.co/WEjqbl14ZN
Dr. Rachel Tate uptoTate ( View Tweet)
#Abstr 1609 - comorbidity clusters in pts with #AS and association w/ disease activity and functional impairment using PSOAS cohort
- identified 5 clusters based on comorbidity
- Depression cluster --> ↑ disease activity and fxnl impairment
@RheumNow #ACR22 https://t.co/cGz4vpOGJ9
Akhil Sood MD AkhilSoodMD ( View Tweet)
Glucocorticoids ≤5 mg/d did not seem to be associated with a reduction of BMD in patients with iRMD and current or prior exposure to GC. Abs 1319 #ACR22 @RheumNow https://t.co/xbYW9y522I https://t.co/QQVjVXoFNf
Dr. Rachel Tate uptoTate ( View Tweet)
Abs 1307 at #ACR22 Romo did not negatively impact knee OA pain or function in postmenopausal women with OP. @RheumNow https://t.co/VMkUnwWt4v https://t.co/fTRPo25GZm
Dr. Rachel Tate uptoTate ( View Tweet)
PC4d≥10 MFI is associated with thrombosis in SLE and predicts future arterial thrombosis. Abs 1442 #ACR22 @RheumNow https://t.co/zg7rrOSALs https://t.co/Hs2eOa2vxJ
Dr. Rachel Tate uptoTate ( View Tweet)
In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO
Dr. Rachel Tate uptoTate ( View Tweet)
Numerically, SLE was more common in cITP patients. Risks include +ANA and female sex. Abs 1461 #ACR22 @RheumNow https://t.co/0kyqlVphac https://t.co/HfYKCMybdL
Dr. Rachel Tate uptoTate ( View Tweet)
While myositis in the setting of SLE was found to be around 5% in Abs 1453, it was not associated with mortality. #ACR22 @RheumNow https://t.co/hLLuYoXsCv https://t.co/44XGhbPxzW
Dr. Rachel Tate uptoTate ( View Tweet)
DAVIX is a promising surrogate outcome measure of vascular disease in SSc. Questions around cost and access remain. Abs 1541 #ACR22 @RheumNow https://t.co/KJgtcG5ah8 https://t.co/NsK7b8fQFt
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow video from #ACR22
Opioid use in PsA and SpA patients
Discussing abstract 1012 by @AlexisOgdie
https://t.co/fKRog1aIkH
Eric Dein ericdeinmd ( View Tweet)
Out work showing JIA pts with sharp decline in needing TKAs, however increased TKA utilizations for tumors!! We are treating inflammatory arthritis better over timein the pediatric population...Natiowide data over 15 years! #ACR22 @Rheumnow abst# 0843 https://t.co/inw41Y1o9r
Bella Mehta bella_mehta ( View Tweet)
TONIGHT! Join us! #ACR22
https://t.co/P0HHEl19hH https://t.co/zjfoNrlYGk
Links:
Dr. John Cush RheumNow ( View Tweet)
One of my personal highlights. History lesson with intersection of medicine. The hilarious @adamjbrown
@RheumNow #ACR22 #rheuminations #factsperminute https://t.co/vDoKLsVfhB
Julian Segan JulianSegan ( View Tweet)
Abst0327 #ACR22 SMART-SLE Monitoring
Some SLE patients with +dsDNA have persistent positivity, others have fluctuations
Anti-dsDNA in persistently positive HR 1.56 for flare risk
Change (up or down!) in dsDNA more than 2x prior visit for fluctuating patients: HR 1.43
@RheumNow https://t.co/YwDPTYWPLu
Eric Dein ericdeinmd ( View Tweet)
Abst0324 #ACR22
How close are we to measuring Interferon Signature in clinical practice?
NCounter and BioFire assays studied - correlated well we each other
Genes: IFI27, IFI44L, IFIT1, RSAD2
SLE higher than RA or FMS, but does not correlate with SLE activity
@RheumNow https://t.co/izpFtj9Pcd
Eric Dein ericdeinmd ( View Tweet)
Abst0326 #ACR22 Anti-Mitochondrial Ab in SLE
Whole mitochondrial (AwMA), AmtDNA or AmtRNA - higher in SLE compared to controls
AwMA predictive of death, AmtDNA and AmtRNA predictive of nephritis
@Rheumnow https://t.co/d98HSHnJVE
Eric Dein ericdeinmd ( View Tweet)
Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis
Factors for SLE transition: younger age, serositis, dsDNA
SSc transition: puffy finger, NFC, or SSc antibodies
No studies wo moderate or high risk of bias
Limited studies on biomarkers for SLE, need more studies
@Rheumnow https://t.co/GofGF8TkCx
Eric Dein ericdeinmd ( View Tweet)
All monster stories end with an unexpected award: A new order
@cuttingforstone at #ACR22 tells the monster story of #covid
“How will history review our story?”
The science will get an A+, but we failed to learn the lessons of history
All was predictable through history
@RheumNow
Eric Dein ericdeinmd ( View Tweet)